|[January 01, 2014]
Vaxenta Inc. Announces Filing of International Patent for Novel Cancer Vaccine
SAN DIEGO --(Business Wire)--
Vaxenta Biotechnologies announces the filing of a Patent Cooperation
Treaty (PCT) application (SN: PCT/US13/55632) to the World Intellectual
Property Organization (WIPO) covering a biological immunotherapeutic
platform against cancer. The international patent has been filed on
August 19th, 2013 with a priority date of August 20th,
2012 based on the provisional filing. This patent application enables
Vaxenta to pursue further stages of development which, once
commercialized, have the potential to provide a novel treatment to allow
for sustainable recovery of cancer patients.
Years of research in the cancer field has culminated in Vaxenta's
discovery and development of an innovative immunotherapeutic vaccine:
XenUvaX. This revolutionary cancer treatment can benefit patients due to
its unique strategy focused on re-awakening the immune system. Although
still in pre-clinical trials, XenUvaX has been proven effective in
training the immune system of rodent species to recognize and target
foreign markers, called antigens, presented on cancer cells.
Additionally, XenUvaX stimulates the immune system to detect cancer
mutations, evasion mechanisms, and growth factors eliminating outlets
for the cancer to evade the vaccine's effect.
Murine studies have dmonstrated efficacy in both colon and melanoma
cancer models. Vaxenta plans to target melanoma as the initial
indication for XenUvaX; however, the research will be expanded to
include prostate, ovarian, bladder, lung and breast cancer. Vaxenta aims
to develop a comprehensive solution through which the body is equipped
with adequate resources to combat multiple forms of cancer.
The founder and CEO of Vaxenta Biotechnologies, Boris Markosian, stated,
"Our Company will excel in the development of an immunotherapeutic agent
effective against various cancer indications and is anticipating more
positive results from ongoing experiments."
The PCT application will allow the company to enforce its intellectual
property rights in over 140 countries as well as help to facilitate its
international expansion within the near future. Vaxenta's goal is to
develop its unique immunotherapeutic vaccine to safely recognize, fight
and prevent cancer with a treatment that will be readily accessible
worldwide in the near future. With safety in mind, Vaxenta plans to
continue to innovate in the space of immunotherapy and provide a natural
alternative to current chemical treatments.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131231005298/en/
[ Back To Technology News's Homepage ]